Agenus stock
AGENNASDAQAgenus Inc., HealthcareISIN US00847G8042
49Score 49 out of 100, Weak
Price and trend
77 / 100
Price history
+55% in one yearThe chart shows daily closes over 20 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Above the 200-day line: the price is 35% above it.
Since July 2026 the 50-day line has been above the 200-day line; the trend has turned up.
Normal: the price is neither overheated nor sold off (RSI 57).
The price is 31% below its 52-week high. Largest decline in 20 years: 100% (April 2007 to March 2025).
Chart figures for advanced users
- SMA 50$7.40
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$5.09
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)57
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDabove the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$2.77
- The lowest closing price of the last twelve months.
- Resistance$9.93
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- Agenus Inc. belongs to the Biotechnology industry (United States) and, with a market value of $430.39M, is number 254 of 296 companies in its industry on MEQIRI.
- For fiscal 2026, analysts expect on average revenue of $124.45M (up 9%) and adjusted earnings per share of $0.27 (down 43.1%).
- MEQIRI Score 49 out of 100 (Weak): rank 389 of 714 in Healthcare, median 53.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- More cash than debtCash $86.94M, financial debt $38.51M.
- High marginNet margin 22.1% over the last 12 months, Biotechnology median −93.3%.Profitability 50
Weaknesses
- DilutionShare count up 245% since 2020.Capital allocation 18
- High debtDebt 20.16 times equity (latest quarter), Biotechnology median 0.09.Stability 11
- Interest barely coveredOperating profit covers interest only 0.9 times.Stability 11
Its standout strengths are valuation and momentum, while capital allocation and stability hold the score back.
Daily figure as of 12 Nov 2026
How the score is calculatedScore overview
Score since yesterday from 48 to 49.
Fundamental quality fluctuates.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansCrash risk high
How well MEQIRI warnsOne of the 30% with the highest crash risk among smaller stocks.
From 2016 to 2025, 36 in 100 such stocks fell 30% or more within a year, against a group average of 23 in 100.
What drives the risk
- weak fundamentals
- high price swings
- price far below its 52-week high
What lowers it
- stable momentum
Valuation
Valuation signal
Possible value trapClosing price of 11 Nov 2026, used by the daily score.
No fair value can be calculated for this stock, so the signal follows the valuation grade.
Possible value trap: looks cheap, but score below 50, high risk, weak balance sheet.
Valuation metrics
No fair value can be calculated for this stock from the available figures.
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In the twelve months to 30 Sep 2026, revenue rose 25.4% on the twelve months before. Revenue has grown strongly since 2012, at around 16% per year. From 2012 revenue is reported differently (for example gross instead of net), so earlier years are not comparable and not shown.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 30%, operating −18%, net 0%. Last 12 months: net 22%. From 2012 revenue is reported differently (for example gross instead of net), so earlier years are not comparable and not shown.
Debt & balance sheet
latest quarterDebt is elevated. Keep an eye on the interest burden and refinancing.
Earnings
- Next earnings
- 15 Mar 2027in 123 days
- Last reported
- 5 Nov 2026EPS reported $0.02 (expected −$0.28)above expectations
Analyst estimates
Earnings estimates have barely changed since 15 Oct 2026.
- Earnings per share
- $0.270.0%
- Revenue
- $124.45M0.0%
- Earnings per share
- −$0.600.0%
- Revenue
- $115.85M0.0%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
Insiders
Open-market purchases and sales by executives, board members and major holders
No open-market purchases or sales in the last 6 months.
Source: Form 4 filings with the US Securities and Exchange Commission. Grants, option exercises, gifts and tax withholdings are hidden. Not a recommendation to buy.
What happened at Agenus
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
714 rated companies in Healthcare
- This company
- 49
- Sector median
- 53
Categories against the sector median
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Biotechnology
The next larger and next smaller companies by market value
- CytomX TherapeuticsCTMX $464.35M31
- Hansa BiopharmaHNSA.ST $458.62M47
- Assembly BiosciencesASMB $455.47M33
- ArvinasARVN $452.5M37
- Gyre TherapeuticsGYRE $451.7M35
- ProthenaPRTA $448.28M43
- Benitec BiopharmaBNTC $440.91M31
- YD BioYDES $435.61M40
ETFs that hold Agenus
Held by 2 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| Xtrackers Russell 2000 UCITS ETF 1CXRS2 | 0.01% | 0.30% | €2.17B |
| State Street SPDR Russell 2000 U.S. Small Cap UCITS ETF (Acc)ZPRR | 0.01% | 0.30% | €4.22B |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 12 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Weak, published since 7 Nov 2026 (in the score history since 31 Oct 2026)
- Valuation signal Fairly valued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.